Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.73 (
urokinase-type plasminogen activator
)
10,685
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tazarotene-induced gene 1 (TIG1) encodes a protein that is a retinoid-regulated tumor suppressor. TIG1 is expressed in most normal tissues, and downregulation of TIG1 expression in multiple cancers is caused by promoter hypermethylation. Kazal-type serine protease inhibitor-2 (
SPINK2
) is a serine protease inhibitor, and the SPINK protein family has been shown to inhibit the expression of
urokinase-type plasminogen activator
(
uPA
). In addition, increased levels of
uPA
and the
uPA
receptor were observed in testicular cancer tissues. This study demonstrated that TIG1 interacts with
SPINK2
in NT2/D1 testicular carcinoma cells. TIG1 and
SPINK2
were highly expressed in normal testis tissues, while low expression levels of TIG1 and
SPINK2
were found in testicular cancer tissues. TIG1 inhibited cell invasion, migration, and epithelial-mesenchymal transition (EMT) of NT2/D1 cells.
SPINK2
enhanced TIG1-regulated
uPA
activity and EMT suppression, while silencing
SPINK2
alleviated TIG1-mediated EMT regulation, cell migration, and invasion. Therefore, the results suggest that the interaction between TIG1 and
SPINK2
plays an important role in the inhibition of testicular cancer cell EMT, and suppression is mediated through downregulation of the
uPA
/uPAR signaling pathway.
...
PMID:Tazarotene-Induced Gene 1 (TIG1) Interacts with Serine Protease Inhibitor Kazal-Type 2 (SPINK2) to Inhibit Cellular Invasion of Testicular Carcinoma Cells. 3188 33
